John Roderick ten Bosch, the Senior Vice President of Laboratory Operations at BillionToOne, Inc., recently reported the sale of 2,834 shares of the company’s Class A common stock. This transaction was executed on October 5, 2026, and is part of a Rule 10b5-1 trading plan adopted by ten Bosch on June 2, 2026. The sales were made at a price of $105.15 per share.
This event is significant as it highlights the ongoing financial management strategies employed by executives within the medical laboratory services sector. Such transactions may indicate a broader trend among industry leaders as they navigate market conditions and personal financial planning.
Background
BillionToOne, Inc. operates in the medical laboratories sector, specifically classified under the SIC code 8071. The company is incorporated in Delaware and has its business address in Menlo Park, California. BillionToOne focuses on innovative laboratory services, which positions it uniquely within the healthcare landscape.
What the Filing Says
The SEC filing, accession number 0002087126-26-000018, details that ten Bosch disposed of 1,417 shares in two separate transactions, resulting in a total of 2,834 shares sold. Following these transactions, ten Bosch retains 20,802 shares of the company.
Impact
This sale may affect stakeholders, including investors and employees, as it reflects the financial decisions of a senior executive. The medical laboratory services industry may also see shifts in executive trading behaviors as a response to market conditions.
What's Next
The filing does not say what happens next.